Phase I/II Study of Pre-operative Docetaxel and Mitoxantrone for High-risk Prostate Cancer

類似資料

• CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel - induced cytotoxicity
  著者:: Qian, David Z., 等
  出版事項: (2010)
• Histological changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in high-risk prostate cancer patients
  著者:: O’Brien, Catherine, 等
  出版事項: (2010)
• Docetaxel and Mitoxantrone Prior to Radical Prostatectomy in Men with High Risk Prostate Cancer: Ten-Year Follow Up and Immune Correlates
  著者:: Bergstrom, Colin P., 等
  出版事項: (2017)
• Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
  著者:: Higano, Celestia S., 等
  出版事項: (2015)
• ID1 enhances docetaxel cytotoxicity in prostate cancer cells via inhibition of p21
  著者:: Geng, Hao, 等
  出版事項: (2010)